HER-3 status by immunohistochemistry in HER-2-positive metastatic breast cancer patients treated with trastuzumab: correlation with clinical outcome
| Autor: | Stefania Gori, Jennifer Foglietta, Maria Grazia Mameli, Lucia Stocchi, Daniela Fenocchio, Paola Anastasi, Daniela Iacono, Rachele Del Sordo, Carlo Basurto, Verena De Angelis, Angelo Sidoni |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
0301 basic medicine
Adult Cancer Research Time Factors Receptor ErbB-3 Receptor ErbB-2 Antineoplastic Agents Breast Neoplasms Kaplan-Meier Estimate Antibodies Monoclonal Humanized 03 medical and health sciences 0302 clinical medicine Biomarkers Tumor Humans Aged Neoplasm Staging Aged 80 and over General Medicine Middle Aged Trastuzumab Immunohistochemistry 030104 developmental biology Treatment Outcome Oncology Drug Resistance Neoplasm 030220 oncology & carcinogenesis Disease Progression Female Neoplasm Grading |
| Zdroj: | Tumori. 98(1) |
| ISSN: | 2038-2529 |
| Popis: | Aims and Background HER-3 signaling might contribute to resistance to trastuzumab. To clarify the role of HER-3 in HER-2-positive breast cancer, it is important to evaluate the level of HER-3 and its correlations with clinical outcome in metastatic breast cancer patients treated with trastuzumab. Methods HER-3 status by immunohistochemistry was evaluated in HER-2-positive metastatic breast cancer patients treated with trastuzumab-based therapy at our institution. Two scorings were utilized for interpreting staining for HER-3, and the correlation between HER-3 status and clinical outcome was evaluated. Results We evaluated HER-3 status in 61 of 76 HER-2-positive metastatic breast cancers treated with trastuzumab-based therapy at our institution from 4/1999 to 3/2006. We observed 55.2% objective responses; median time to progression and overall survival from start of trastuzumab therapy were 9.6 months (0.921–78.87) and 29.1 months (1.4–129.5+), respectively. With a cutoff of 50% staining tumor cells, we found 30 HER-3-negative and 31 HER-3-positive tumors. HER-3 status was not significantly associated with clinical outcome, but a shorter time to progression and overall survival were observed in patients with HER-3-positive tumors. Conclusions HER-3 status by immunohistochemistry was not significantly associated with clinical outcome in HER-2-positive metastatic breast cancer patients. Further studies are necessary to evaluate the prognostic and predictive role of HER-3. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|